偑傫庬暿僔儏儀僣丂儗僕儊儞堦棗僀僠儔儞
僒僈偟偺儗僕儊儞傪僽儔僂僓偺専嶕働儞僒僋婡擻僉僲僂専嶕働儞僒僋偟偰偔偩偝偄丅
偑傫柤徧儊僀僔儑僂傪僋儕僢僋偡傞偲僇僋偑傫僔儏儗僕儊儞偺徻嵶僔儑僂僒僀儁乕僕偵堏峴僀僐僂偟傑偡丅
僩僢僾偵儌僪
MDS 儗僕儊儞儊僀
亂S.C.亃價僟乕僓扨撈僞儞僪僋帯椕僠儕儑僂
懡敪惈僞僴僣僙僀崪悜庮僐僣僘僀僔儏 儗僕儊儞儊僀
亂S.C.亃BD乮儀儖働僀僪旂壓拲僸僇僠儏僂+僨僉僒儊僞僝儞乯
亂S.C.亃VRD姲夝摫擖僇儞僇僀僪僂僯儏僂儀儖働僀僪旂壓拲僸僇僠儏僂亄儗僽儔儈僪亄僨僉僒儊僞僝儞
DLd(1僒僀僋儖)
DLd乮2僒僀僋儖)
DLd乮3乣6僒僀僋儖乯
DLd乮7僒僀僋儖埲崀)
Eld(1乣2僒僀僋儖)
Eld乮3僒僀僋儖埲崀僀僐僂
KRd乮2乣12僒僀僋儖)
VMP姲夝摫擖乮儀儖働僀僪旂壓拲乯
VMP堐帩乮儀儖働僀僪旂壓拲乯
KD乮2僒僀僋儖埲崀)
PBD椕朄乮1乣8僒僀僋儖栚乯
PBD椕朄乮9僒僀僋儖栚埲崀乯
weekly KD椕朄乮1僒僀僋儖栚乯
亂僔儑乕僩亃weekly KD椕朄乮2僒僀僋儖埲崀乯
EPD乮1僒僀僋儖乯
EPD乮2僒僀僋儖乯
EPD乮3僒僀僋儖乯
EPD乮4僒僀僋儖埲崀乯
亂S.C.2榞亃DBd椕朄乮1僒僀僋儖栚乯
亂S.C.2榞亃DBd椕朄乮2乣3僒僀僋儖栚乯
亂S.C.2榞亃DBd椕朄乮4乣8僒僀僋儖栚乯
亂S.C.2榞亃DBd椕朄乮9僒僀僋儖栚埲崀乯
DCd椕朄乮2僒僀僋儖栚乯
DCd椕朄乮3乣6僒僀僋儖栚乯
亂S.C.2榞亃D-MPB椕朄乮2乣9僒僀僋儖栚乯
亂S.C.亃DPd椕朄乮1僒僀僋儖栚乯
亂S.C.亃DPd椕朄乮2僒僀僋儖栚乯
亂S.C.亃DPd椕朄乮3-6僒僀僋儖栚乯
亂S.C.亃DPd椕朄乮7僒僀僋儖栚埲崀乯
亂2榞亃IsaPd椕朄乮1僒僀僋儖栚乯
亂2榞亃IsaPd椕朄乮2僒僀僋儖栚埲崀乯
旕儂僕僉儞儕儞僷庮 儗僕儊儞儊僀
亂2儚僋亃R-CHOP椕朄儕儑僂儂僂乮1僯僠僇儞
R+儀儞僟儉僗僠儞乮2擔娫僯僠僇儞
R
G-Bend
R+儀儞僟儉僗僠儞椕朄
G-Bend(1僒僀僋儖)
G-Bend(俀僒僀僋儖埲崀)
僈僓僀僶扨撈堐帩椕朄
亂2榞亃R-THP-COP乮70-79嵨乯(1僯僠僇儞
亂2榞亃R-THP-COP乮80嵨埲忋乯(1擔娫乯
R-CVP乮1擔娫乯
R-GCD
亂2榞亃Pola-BR椕朄乮2僒僀僋儖栚埲崀乯
亂2榞亃Pola-R-CHP椕朄乮2-6僒僀僋儖栚乯
亂僔儑乕僩亃MTX-HOPE椕朄
A-CHP
儂僕僉儞儕儞僷僔儏 儗僕儊儞儊僀
ABVD
A-AVD
亂籍澳亃僉僀僩儖乕僟
媫惈僉儏僂僙僀崪悜惈僐僣僘僀僙僀敀寣昦僴僢働僣價儑僂 儗僕儊儞儊僀
Ven亄LDAC
Ven亄AZA
彫嵶朎僔儑僂僒僀儃僂僴僀偑傫 儗僕儊儞儊僀
亂籍澳亃ALM
亂僔儑乕僩亃nab-PTX扨撈僞儞僪僋
亂僔儑乕僩亃NSCLC-Durvalmab
亂僔儑乕僩亃NSCLC-Nivolumab
CBDCA+nab-PTX 1, 8, 15
Doc+Ram
non-sq: Pembro+CBDCA+ALM
NSCLC-Atezolizumab
NSCLC-Pembrolizumab
Sq: Pembro+CBDCA+nabPTC 
亂僔儑乕僩亃Atezo+Bev堐帩椕朄
GEM+VNR丂biweekly
NSCLC-Ipi-Nivo
亂僔儑乕僩亃NSCLC-Nivolumab 4-week intervals
non-Sq: Pembro+ALM堐帩椕朄
NSCLC-Pembrolizumab 6-week intervals
VNR1丆8
亂籍澳亃PEM
亂僔儑乕僩亃nab-PTX扨撈僞儞僪僋
亂僔儑乕僩亃NSCLC-Durvalmab
亂僔儑乕僩亃NSCLC-Nivolumab
CBDCA+nab-PTX 1, 8, 15
Doc+Ram
non-sq: Pembro+CBDCA+ALM
NSCLC-Atezolizumab
NSCLC-Pembrolizumab
Sq: Pembro+CBDCA+nabPAC 
亂僔儑乕僩亃Atezo+Bev堐帩椕朄
GEM+VNR丂biweekly
NSCLC-Ipi-Nivo
亂僔儑乕僩亃NSCLC-Nivolumab 4-week intervals
non-Sq: Pembro+ALM堐帩椕朄
NSCLC-Pembrolizumab 6-week intervals
VNR1丆8
Sq: Pembro堐帩椕朄
亂2榞亃CBDCA+PTX 1
CBDCA+PTX 1丆8丆15
DOC
亂籍澳亃GEM丂1丆8
亂僔儑乕僩亃BV乮傾僶僗僠儞扨撈乯
non-Sq丂Pembro+CBDCA+PEM
non-Sq: Pembro+PEM堐帩椕朄
亂2榞亃Atezo+Bev+CBDCA+PAC
RAM+Erlotinib
亂2榞亃Atezo+CBDCA+nab-PTX
CBDCA+TS-1
亂籍澳亃僥僙儞僩儕僋弍屻曗彆壔妛椕朄
彫嵶朎僔儑僂僒僀儃僂僴僀偑傫 儗僕儊儞儊僀
亂2儚僋亃CDDP+CPT-11 1, 8, 15
亂2榞亃CBDCA+ETP1丆2丆3
AMR丂1丆2丆3
SCLC-Atezo堐帩椕朄
CBDCA+ETP1丆2丆3
SCLC-durvalumab-CBDCA-ETP
NGT
SCLC-maintenance-Durvalumab
摢栩晹僩僂働僀僽偑傫 儗僕儊儞儊僀
亂僔儑乕僩亃僆僾僕乕儃
僷僋儕僞僉僙儖+僙僣僉僔儅僽丂弶夞
僷僋儕僞僉僙儖+僙僣僉僔儅僽乮2夞栚僇僀儊埲崀僀僐僂
亂籍澳亃儁儉僽儘儕僘儅僽
傾乕價僞僢僋僗扨撈乮2僐乕僗栚埲崀乯
亂僔儑乕僩亃僆僾僕乕儃(4廡娫娫妘乯
戝挵僟僀僠儑僂偑傫 儗僕儊儞儊僀
XELOX乮僛儘乕僟+L-OHP乯
儀僋僥傿價僢僋僗乮6 mg/kg乯+FOLFIRI
CPT-11+Pmab
FOLFIRI+僓儖僩儔僢僾
FOLFIRI+儔儉僔儖儅僽
FOLFOXIRI+Bev
UFT+LV+Bev
Weekly-Cetu+FOLFOX6乮KRAS栰惗宆乯
傾僶僗僠儞乮10 mg/kg乯+FOLFIRI
傾僶僗僠儞乮10 mg/kg乯+mFOLFOX6
傾僶僗僠儞乮5 mg/kg乯+FOLFIRI
傾僶僗僠儞乮7.5 mg/kg乯+XELOX 
亂2榞亃mFOLFOX6+Pmab
傾乕價僞僢僋僗扨撈乮2僐乕僗栚埲崀乯
mFOLFOX6
傾僶僗僠儞 (5mg/kg) + mFOLFOX6
5-FU+LV+Bev乮FOLFOXIRI+Bev屻堐帩椕朄乯
IRIS+傾僶僗僠儞 (傾僶僗僠儞+CPT11+TS-1 (SRIM 帋尡)
儀僋僥傿價僢僋僗丂扨撈丂乮6mg/kg乯
S-1+IRI+BEV 俁廡儗僕儊儞
SOX + 傾僶僗僠儞 (TS-1 + L-OHP + 傾僶僗僠儞)
w-傾乕價僞僢僋僗 + bi- CPT-11
亂籍澳亃TAS102亄BV
SOX  (TS-1 + L-OHP )
BEACON
戝挵娻 PER+HER 
儘儞僒乕僼+Bev
JACCRO CC-13丗FOLFOXIRI+Bev
偑傫 儗僕儊儞儊僀
偑傫儓僂乯SOX乮TS-1+L-OHP乯
偑傫儓僂乯XELOX乮僛儘乕僟+L-OHP)
亂僔儑乕僩亃GC-Nivolumab
CPT-11 扨撈僞儞僪僋
SP+HER乮short hydration乯
TS-1 + Docetaxel椕朄
weekly PTX+儔儉僔儖儅僽
(堓偑傫梡乯mFOLFOX6
亂籍澳亃GC-Nivolumab (4w)
nab-PTX+RAM
 FOLFOX亄Nivo
SOX+HER
SOX亄Nivo
weekly-PTX
XELOX亄Nivo
怘摴僔儑僋僪僂偑傫 儗僕儊儞儊僀
怘摴僔儑僋僪僂偑傫乯weekly PTX
3-weekly TXT
怘摴偑傫-Nivolumab
怘摴偑傫-Nivolumab (4w)
FP亄Nivo(2廡枅)
亂2榞亃FP亄Pembro (6僐乕僗傑偱)
亂籍澳亃怘摴娻乚Nivolumab乮2w乯乮弍屻曗彆乯
亂籍澳亃怘摴娻乚Nivolumab乮4w乯乮弍屻曗彆乯
IPI亄Nivo(2廡枅)
IPI亄Nivo(3廡枅)
鋁憻僗僀僝僂偑傫 儗僕儊儞儊僀
亂籍澳亃GEM扨撈 (帯椕梡)
FOFIRINOX
nab-PTX+GEM
亂2榞亃Nal-IRI+5-FU/LV
GEM扨撈 (帯椕梡)
GEM 1, 8 + TS-1 (2搳1媥)丂(帯椕梡)
抇摴僞儞僪僂偑傫 儗僕儊儞儊僀
亂2儚僋亃GEM嘆嘒+CDDP嘆嘒
GCS椕朄
亂2榞亃Durvalumab+GEM+CDDP椕朄
娞憻僇儞僝僂偑傫 儗僕儊儞儊僀
儔儉僔儖儅僽扨嵻僞儞僓僀
Atezo+Bmab
僯儏僂偑傫 儗僕儊儞儊僀
3wk HER
GEM丂1丆8
CMF亂p.o.亃乮CPA+MTX+5-FU乯
DOC100
Doc75+PER+HER
EC80乮EPI+CPA乯
FEC100乮5-FU+EPI+CPA乯
PTX+PER亄HER 
TC椕朄儕儑僂儂僂亂iv亃乮TXT+CPA亂iv亃乯
wPTX (12wk)
wPTX+儀僶僔僘儅僽
僄儕僽儕儞
簇剔剌+PER+HER
僇僪僒僀儔
亂籍澳亃2w VNR
僄儞僴乕僣
GEM+PER亄HER (2僐乕僗栚埲崀)
Pembro亄CG
Pembro亄EC (NAC2)
Pembro亄wPTX亄wCBDCA (NAC1)
VNR 1丆8
亂籍澳亃3wABX (傾僽儔僉僒儞)
XT 椕朄 (DOC60+Xeloda)
GEM+CBDCA
簇剔剌+PER+HER(俀僐乕僗栚埲崀)
VNR+PER亄HER (2僐乕僗栚埲崀)
擼庮釃僲僂僔儏儓僂 儗僕儊儞儊僀
亂僔儑乕僩亃傾僶僗僠儞扨撈僞儞僪僋
僕儞偑傫 儗僕儊儞儊僀
亂僔儑乕僩亃僥儉僔儘儕儉僗椕朄儕儑僂儂僂
亂僔儑乕僩亃僯儃儖儅僽椕朄儕儑僂儂僂僕儞偑傫乯
恡娻僕儞僈儞僯儃儖儅僽+僀僺儕儉儅僽丂嵟弶僒僀僔儑4僐乕僗
傾儀儖儅僽亄傾僉僔僠僯僽暪梡椕朄
莆拶咸迼脰@ 4廡娫徊纲乮恡娻 2nd line乯
恡娻 瓦烟捋亟咸6廡娫亄狈剂铺迺箺p椕朄
菜邅E莆迣 莆拶咸迴P迼脰@ 4w徊纲乮恡娻 乯
亂籍澳亃僯儃儖儅僽亄僇儃僓儞僠僯僽暪梡椕朄
亂籍澳亃僯儃儖儅僽4廡娫亄僇儃僓儞僠僯僽暪梡椕朄
亂籍澳亃恡嵶朎娻 瓦萏捋亟尴剔3廡亄谳兽疗剔暪梡椕朄
亂籍澳亃恡嵶朎娻 瓦萏捋亟尴剔6廡亄谳兽疗剔暪梡椕朄
銷泖儃僂僐僂偑傫 儗僕儊儞儊僀
GEM+CBDCA椕朄
UC-Pembrolizumab
擜楬忋旂娻 瓦烟捋亟咸迼脰@ 6廡娫徊纲
擜楬忋旂娻 僷僪僙僽椕朄
擜楬忋旂娻 傾儀儖儅僽堐帩椕朄
(夵掶斉)GC
GEM+CBDCA椕朄(30<CCr<60 CDDP晄壜徢椺乯
亂籍澳亃UC弍屻僯儃儖儅僽椕朄 2廡娫僒僀僋儖
亂籍澳亃UC弍屻僯儃儖儅僽椕朄 4廡娫僒僀僋儖
慜棫態僛儞儕僣僙儞偑傫 儗僕儊儞儊僀
Cabazitaxel椕朄儕儑僂儂僂
Triweekly DOC
埆惈傾僋僙僀崟怓庮僐僋僔儑僋僔儏 儗僕儊儞儊僀
亂僔儑乕僩亃MM biwekly Nivolumab
MM Nivolumab adjuvant 4W
MM丂Pembrolizumab
MM Nivolumab 4W
Nivolumab+Ipilimumab
亂僔儑乕僩亃MM-儁儞僽儘儕僘儅僽丂400噐
亂籍澳亃MM Nivolumab 4W
棏憙儔儞僜僂偑傫 儗僕儊儞儊僀
亂2儚僋亃PTX+CBDCA
亂2儚僋亃PTX+CBDCA+Bev
亂僔儑乕僩亃GEM扨撈僞儞僪僋嘆嘒嘚
DOC+CBDCA
PLD+Bev
CPT-11+CDDP
PLD+CBDCA
dd-PTX 嘆 嘒 嘚 + CBDCA 嘆
BEP椕朄
Bev逸门萁
weeklyPTX+Bev
DOC+CBDCA+Bev
NGT
巕媨懱僔僉儏僂僞僀偑傫 儗僕儊儞儊僀
AP椕朄儕儑僂儂僂
PTX+CBDCA
亂籍澳亃儗儞價儅+僉僀僩儖乕僟(200mg q3w)
DP椕朄
巕媨僔僉儏僂働僀偑傫 儗僕儊儞儊僀
亂2榞亃俠俹俿亅11+俶俢俹
TC-Bev
CPT-11扨撈 嘆 嘒 嘚
亂2榞亃Pem+TCBev
Pem+Bev堐帩椕朄
屌宍僐働僀偑傫 儗僕儊儞儊僀
MSI-High丂pembro
亂籍澳亃TMB-High 3廡 Pembro
傾儈儘僀僪乕僔僗 儗僕儊儞儊僀
亂S.C亃DCyBorD椕朄乮1僒僀僋儖栚乯
亂S.C亃DCyBorD椕朄乮2僒僀僋儖栚乯
亂S.C亃DCyBorD椕朄乮3-6僒僀僋儖栚乯
亂S.C亃DCyBorD椕朄乮7僒僀僋儖栚埲崀乯
媫惈僉儏僂僙僀T儕儞僷僙僀敀寣昦僴僢働僣價儑僂 儗僕儊儞儊僀
億僥儕僕僆扨撈僞儞僪僋
擏庮僯僋僔儏 儗僕儊儞儊僀
亂籍澳亃僄儕僽儕儞
DXR
尨敪晄柧娻僎儞僷僣僼儊僀僈儞 儗僕儊儞儊僀
亂籍澳亃Nivo丂CUP丂240mg q2w